New York, Dec. 12 - AngioChem Inc. announced it obtained $6 million of venture capital financing.
BDC Venture Capital and Vimac Milestone Medica Fund led the investors.
AngioChem said it expects to file an investigational new drug application for the treatment of brain cancer in late 2006 and enter a phase 1/2 clinical trial in 2007.
"The technologies developed by AngioChem will allow the design of new therapeutics that could cross the blood brain barrier and target the brain. This will allow the development of new therapeutics having a higher efficacy for the treatment of central nervous system disorders," said Richard Beliveau, scientific founder of AngioChem, in a news release.
AngioChem is based in Laval, Quebec.
| Issuer: | AngioChem Inc.
|
| Issue: | Venture capital financing
|
| Amount: | $6 million
|
| Investors: | BDC Venture Capital, Vimac Milestone Medica Fund (leads)
|
| Announcement date: | Dec. 12
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
